Japanese

Department of Clinical Product Development

Clinical Product Development department is one of the departments in the Clinical Medicine and Research was established newly on April 1, 2012.

Department of Clinical Product DevelopmentThis is a newly established department in response to the Global Strategy on public health, innovation and intellectual property (resolution WHA61.21). The resolution calls for the enhancement of health-needs driven research and development to address diseases that disproportionately affect developing countries. The establishment of this department was supported by the Department of Academic and Research Promotion, Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. MEXT continues to support the department until its full development.

Members

  • Professor Laothavorn Juntra
  • Associate Professor Nguyen Huy Tien
  • Assistant Professor Chisato Narahara
  • Visiting Professor Kesara Na-Bangchang
  • Visiting Researcher Tullayakorn Plengsuriyakarn
  • Assistant Sayuri Delaney
  • Graduate Student Nut Koonrungsesomboon
  • Graduate Student Teerachat Sae-heng

To the Site of our department»

The department focuses on

  1. Building capacity of individuals for innovation in health product.
  2. Strengthening capability of the local research institutions in providing an enabling environment, including infrastructure for product R&D.
  3. Strengthening research institutes network for knowledge sharing and exchange, and for R&D technology transfer activities. The emphasis will be on developing products for public health needs to address the issues of inequity in health.
  4. Filling the gap of health knowledge.

The activities

a) Training

  1. Two- week course on Product Research and Development for public health needs.
  2. Three-day course on Bioethics.
  3. Responsible Research.

b) Research

  1. Identification and further development of Herbal Medicine and novel small compounds for Breast cancer, Cholangiocarcinoma and Malaria.
  2. Validating the Enhance Informed Consent for clinical trials.
  3. Host pharmacogenomics and malaria virulence.
  4. Revolution of P.falciparum K13 in Thailand.

c) Network

  1. Coordination of Product Research and Development (PRD) Network
  2. Coordination of research ethics global network-Strategic Initiative for Developing Capacity in Ethical Review (SIDCER)
         Recent main research achievement
1. Saeheng et al. Eur J Clin Pharmacol 2018;74(11):1365-1376.
2. Juntra et al. BMC Medical Ethics 2018;19(1):79.
3. Koonrungsesomboon et al. Arch Dis Child Fetal Neonatal Ed 2018;103(5):F403-F407.
4. Emmanuel et al. Ann Clin Microbiol Antimicrob 2018;17(1):35.
5. Na-Bangchang K et al. Evid Based Complement Alternat Med 2017;2017:5929234.

Return to Top of Department»